Cytel: Global experts in HEOR & RWE

At Cytel, we provide the deep insights and expertise necessary for making confident development decisions. Our global team helps generate evidence that complements traditional randomized clinical trials, accelerates submissions, expands indications, and supports health-economic decision-making.

Connect with our HEOR & RWE experts by registering for our upcoming webinar series below or meet our team in Boston at ISPOR!

ISPOR US 2023

We are excited to see you at ISPOR US 2023 where, once again, Cytel is honored to have the greatest number of Issue Panels & Workshop presentations, a testament to our commitment as a scientific and methodological leader. This year, visit us at Booth #1023 to connect with our HEOR & RWE experts on topics such as RWE and Health Disparities in HTAs, Quantitative Bias Analysis, RWE Sources in HTA Submissions and more.

Fill out the form to pre-book a meeting with the Cytel team to learn more about our innovative offerings in HEOR & RWE.

Webinar Series: HEOR & RWE

Unable to attend ISPOR this year or interested in joining the conversation before we meet in person? Register below for our webinar series:

Meet with us at ISPOR

Webinar Series: Early patient preferences for patient-focused drug development

Webinar Series Speakers:

Dr. Thomas Wilke, Contract Principle, RWA, Cytel
Dr. Tommi Tervonen, Chief Scientist, Kielo Research

This two-part webinar series introduces the value of patient preferences in early drug development. Speakers discuss how to use patient preferences to:

Gain early patient insights to optimize clinical trial enrollment
Demonstrate that your endpoints are patient relevant
Ensure your target product profile describes a treatment desired by the patients
Measure the value of patient-reported outcome (PRO) endpoints
Demonstrate positive benefit-risk using patient preferences
Co-develop treatment with patients
Confirm treatment value from patient perspective to investors and for reimbursement
Demonstrate treatment preference in diverse groups of patients.

Webinar Series: Make better decisions using innovative comparative effectiveness methods - Cytel’s expertise series

Webinar Series Speakers:

Bart Heeg, Vice President HEOR Global, Cytel
Maria Rizzo, Vice President HEOR EU, Cytel
Caitlyn Daly, Senior Research Consultant, Statistics, Cytel
Eric Mackay, Research Principal, Statistics, Cytel
Gabriel Tremblay, Vice President, Advanced Analytics, Cytel
Paul Arora, Vice President, Advanced Epidemiology
Kristian Thorlund, SVP Real World Analytics, Cytel
Grammati Sarri, Senior Research Principal, Cytel

This four-part webinar series will introduce novel comparative effectiveness methods and highlight how these can be used to better support product value. The first webinar will explore the importance of ITCs in Health Technology Assessments (HTAs) as well as the recent challenges with ITCs and discuss the INGRESSA framework for selecting appropriate methodology for comparative effectiveness. The remaining three webinars will discuss specific methods for anchored and un-anchored analyses, as well as methods addressing premature outcomes data and use of real-world evidence in comparative effectiveness.

Key Presentations at ISPOR

Once again, we are honored to have the greatest number of Issue Panels & Workshop presentations, a testament to our commitment as a scientific and methodological leader. Connect with our experts at Booth #1023 on topics such as RWE and Health Disparities in HTAs, Quantitative Bias Analysis, RWE Sources in HTA Submissions, and more.

Click below to view our presentations!

HEOR & RWE Focused Blogs

New Linked Database Expands Potential of RWE: A Unique Opportunity for Multiple Sclerosis Research

Real-world data has been increasingly used to answer questions related to the course, prognosis, and treatment of...

Can RWE Help Restore Decades of Health Inequalities? Yes, and Here’s How

Health inequalities are an enduring issue that can be exacerbated by clinical trial recruitment that does not reflect...

Comparative Effectiveness: Methods and Techniques for Better Decision-Making

Health technology assessment (HTA) submissions require cost effectiveness analyses based on comparative effectiveness..

Real World & Advanced Analytics

Through our advanced analytics, Cytel provides the richer, deeper insights necessary for making confident development decisions. We generate evidence which complements traditional randomized clinical trials, accelerates submissions, expands indications, and supports health-economic decision-making.

Click to learn more about our HEOR, RWE, LiveSLR, and more offerings.

Cytel HEOR & RWE